Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Miracle-G: Multimodal Treatment in Limited Metastatic Gastric/GEJ Cancer
NCT06121700Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Jan 2023
- Primary completion
- Dec 2025
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Fudan University. Primary endpoint: Overall Survival at 5 years. Started Jan 2023; status: recruiting.
02
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06121700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06121700.